The X-Linked Adrenoleukodystrophy (X-ALD) and Oxidative Stress

References

• Moser H W. Adrenoleukodystrophy: Phenotype, genetics, pathogenesis, and therapy. Brain 1997; 120: 1485–1508
   PubMed Web of Science ®Google Scholar
• Dubois-Dalcq M, Feigenbaum V, Aubourg P. The neurobiology of X-linked adrenoleukodystrophy, a demyelinating peroxisomal disorder. Trends Neurosci 1999; 22: 4–12
   PubMed Web of Science ®Google Scholar
• Kemp S, Pujol A, Waterham H R, van Geel B M, Bohem C D, Raymond G V, Cutting R G, Wanders R, Moser H W. ABCD1 mutation and X-linked adrenoleukodystrophy mutation database: Role in diagnosis and clinical correlation. Human Mutation 2001; 18: 499–515
   PubMed Web of Science ®Google Scholar
• Sarde C O, Mosser J, Kioschis P, Kretz C, Vicaire S, Aubourg P, Poustka A, Mandel J L. Genomic organisation of the adrenoleukodystrophy gene. Genomic 1994; 22: 13–20
   PubMed Web of Science ®Google Scholar
• Leonard A E, Pereira S L, Sprecher H, Huang Y S. Elongation of long-chain fatty acids. Progr Lipid Res 2004; 43: 36–54
   PubMed Web of Science ®Google Scholar
• , WWW.STOPALD.Org
   Google Scholar
• Moser H W, Moser K D, Smith A, Bergin A, Borel A J, Sine J, Sine O C, Merette C, Ott J, Krivit W, Shapiro E. Adrenoleukodystrophy: Phenotypic variability and implications for therapy. J Inherit Metab Dis 1992; 15: 645–664
   PubMed Web of Science ®Google Scholar
• Moser H W. Adrenoleukodystrophy: Phenotype, genetics, pathogenesis, and therapy. Brain 1997; 120: 1485–1508
   PubMed Web of Science ®Google Scholar
• Kemp S, Valianpour F, Denis S, Ofrman R, Sanders R J, Mooyer P, Barth P G, Wanders J A. Elongation of very long-chain fatty acids is enhanced in X-linked adrenoleukodystrophy. Mol Gen Metab 2005; 84: 144–151
   PubMed Web of Science ®Google Scholar
• Singh I, Pahan K, Khan M. Lovastatin and sodiun phenylacetate normalise the levels of very long-chain fatty acids in skin fibroblast of X-adrenoleukodystrophy. 1998; 426: 342–346
   Google Scholar
• Singh I, Khan M, Key L, Pai S. Lovastatin for X-linked adrenoleukodystrophy. N Eng J Med 1998; 339: 702–703
   PubMed Web of Science ®Google Scholar
• Senior K. Lorenzo’s oil may help to prevent ALD symptoms. Lancet Neurl 2002; 1: 468
   PubMed Web of Science ®Google Scholar
• Suzuki Y, Imamura A, Shimazawa N, Kondo N. The clinical course of childhood and adolescent adrenoleukodystrophy after Lorenzo’s oil. Brain Devel 2001; 23: 30–33
   PubMed Web of Science ®Google Scholar
• Moser A B, Borel A, Odone A, Naidu S, Cornblath D, Sanders D B, Moser A. A new dietary therapy for adrenoleukodystrophy: Biochemical and preliminary clinical results in 36 patients. Ann Neurol 1987; 21: 240–249
   PubMed Web of Science ®Google Scholar
• Van Geel B M, Assies J, Haverkort E B, Koelman J H, Verbeeten B, Wanders R J, Barth P G. Progression of abnormalities in adrenoleukodystrophy and neurological asymptomatic X-linked adrenoleukodystrophy despite treatment with “Lorenzo’s oil”. J Neurol Neurosurg Psychiatry 1999; 67: 290–299
   PubMed Web of Science ®Google Scholar
• Halliwell B. Free radicals, antioxidants, and human disease: Curiosity, cause or consequence?. Lancet 1994; 344: 721–724
   PubMed Web of Science ®Google Scholar
• Vargas C R, Wajner M, Sirtori L R, Goulart L, Chiochetta M, Coelho D, Latini A, Lleusy S, Bello-Klein A, Giugliani R, Deon M, Mello C F. Evidence that oxidative stress in patients with X-linked adrenoleukodystrophy. Biochim Biophy Acta 2004; 1688: 26–32
   PubMed Web of Science ®Google Scholar
• Al-Omar M, Beedham C, Al-Sarra I. Pathological roles of reactive oxygen species and their defence mechanisms. Saudi Pharm J 2004; 12: 1–18
   Google Scholar
• Schroeter M L, Mertsch K, Giese H, Muller S, Sporbert A, Hickel B, Blasing I E. Astrocytes enhance radical defence in capillary endothelial cells constituting the blood-brain barrier. FEBS Lett 1999; 449: 241–244
   PubMed Web of Science ®Google Scholar
• Cooper A JL. The role of glutathione in the nervous system: Role of astrocytes in maintaining cerebral glutathione homeostasis and in protecting the brain against xenobiotics and oxidative stress, C A. Shaw. Taylor and Francis, Washington 1998; 91–115
   Google Scholar
• Jain A, Martensson J, Stole E, Auld P AM, Meister A. Glutathione deficiency leads to mitochondrial damage in brain. Proc Natl Acad Sci USA 1991; 88: 1913–1917
   PubMed Web of Science ®Google Scholar
• Bayol-Denizot C, Daval J-L, Netter P, Minn A. Xenobiotic-mediated production of superoxide by primary cultures of rat cerebral endothelial cells, astrocytes, and neurones. Biochim Biophys Acta 2000; 1497: 115–126
   PubMed Web of Science ®Google Scholar
• Travis J. Glia: the brain’s other cells. Science 1994; 266: 970–972
   PubMed Web of Science ®Google Scholar
• Magistretti P J. Fundamental neuroscience: Brain energy metabolism. Chap. 14. Academic Press. 1999; 389–413
   Google Scholar
• Kanner J, German J B, Kinsella J E. Initiation of lipid peroxidation in biological systems. CRC Crit Rev Food Sci Nut 1987; 25: 317–364
   Google Scholar
• Shaw P J. Science, medicine, and the future motor neuron disease. British Medical J 1999; 318: 1118–1121
   PubMed Web of Science ®Google Scholar
• Williams D B, Windebank A J. Motor neuron disease (amyotrophic lateral sclerosis). Mayo Clin Proc 1991; 66: 54–82
   PubMed Web of Science ®Google Scholar
• Browne S E, Bowling A C, MacGarvey U, Bailk M J, Berger S C, Muqit M K, Bird E D, Beal M F. Oxidative damage and metabolic dysfunction in Huntington’s disease: Selective vulnerability of basal ganglia. Ann Neurol 1997; 41: 646–653
   PubMed Web of Science ®Google Scholar
• Doble A. The role of excitotoxicity in neurodegenerative disease: Implications of therapy. Pharmacol Ther 1999; 81: 163–221
   PubMed Web of Science ®Google Scholar
• Maimone D, Dominici R, Grimaldi L ME. Pharmacogenomics of neurodegenerative diseases. Eur J Pharmacol 2001; 413: 11–29
   PubMed Web of Science ®Google Scholar
• Milonas L. Amyotrophic lateral sclerosis: An introduction. J Neurol 1998; 245: S1–S3
   PubMed Web of Science ®Google Scholar
• Ames B N, Shigenaga M K, Hagen T M. Oxidants, antioxidants, and the degenerative diseases of aging (cancer/mutation/endogenous DNA adducts/oxygen radicals). Proc Natl Acad Sci USA 1993; 90: 7915–7922
   PubMed Web of Science ®Google Scholar
• Hall E D, Andrus P K, Oostveen J A, Fleck T J, Gurney M E. Relationship of oxygen radical-induced lipid peroxidative damage to disease onset and progression in a transgenic model of familial ALS. J Neurosci Res 1998; 53: 66–77
   PubMed Web of Science ®Google Scholar
• Biase A D, Benedetto R D, Fiorentini C, Travaglione S, Salvati S, Attorri L, Pietraforte D. Free radical release in C6 glial cells enriched in hexacosanoic acid: Implication for X-liked adrenoleukodystrophy pathogenesis. Neurochem Int 2004; 44: 215–221
   PubMed Web of Science ®Google Scholar
• Larkin M. Parkinson’s disease research moves on briskly. Lancet 1999; 353: 566
   PubMed Web of Science ®Google Scholar
• Alexi T, Borlongan C V, Faull R LM, Williams C E, Clark R G, Gluckman P D, Hughes P E. Neuroprotective strategies for basal ganglia degeneration: Parkinson’s and Huntington’s disease. Prog Neurobiol 2000; 60: 409–470
   PubMed Web of Science ®Google Scholar
• Burke W J, Li S W, Zahm D S, Macarthur H, Kolo L L, Westfall T C, Anwar M, Glickstein S B, Ruggiero D A. Catecholamine monoamine oxidase a metabolite in adernergic neurons is cytotoxic in vivo. Brain Res 2001; 891: 218–227
   PubMed Web of Science ®Google Scholar
• Yatin S M, Varadarajan S, Butterfield D A. Vitamin E prevents Alzheimer’s amyloid β-peptide (1–42)-induced neuronal protein oxidation and reactive oxygen species production. J Alzheimer’s Dis 2000; 2: 123–131
   PubMedGoogle Scholar
• Perry G, Castellani R J, Hirai K, Smith M A. Reactive oxygen species mediate cellular damage in Alzheimer disease. J Alzheimer’s Dis 1998; 1: 45–55
   PubMedGoogle Scholar
• Mecocci P, MacGarvey U, Beal M F. Oxidative damage to mitochondrial DNA is increased in Alzheimer’s disease. Ann Neurol 1994; 36: 747–750
   PubMed Web of Science ®Google Scholar
• Behl C. Alzheimer’s disease and oxidative stress: implications for novel therapeutic approaches. Prog Neurobiol 1999; 57: 301–323
   PubMed Web of Science ®Google Scholar
• Reiter R J, Cabera J, Sainz R M, Mayo J C, Manchester L C, Tan D-X. Melatonin as a pharmacological agent against neuronal loss in experimental models of Hunting-ton’s disease, Alzheimer’s disease and Parkinsonism. Ann New York Aca Sci 1999; 890: 471–485
   PubMed Web of Science ®Google Scholar
• Tan D-X, Manchester L C, Reiter R J, Plummer B F, Limson J, Weintraub S T, Qi W. Melatonin directly scavenges hydrogen peroxide: A potentially new metabolic pathway of melatonin biotransformation. Free Radic Biol Med 2000; 29: 1177–1185
   PubMed Web of Science ®Google Scholar
• Al-Omar M A, El-Subbagh H I, Beedham C, Smith J A. Role of molybdenum hydroxylases in diseases. Saudi Pharm J 2005; 13: 1–13
   Google Scholar
• Sun A Y, Chen Y-M. Oxidative stress and neurodegenerative disorders. J Biomed Sci 1998; 5: 401–414
   PubMed Web of Science ®Google Scholar